April 15, 2013 — Tomosynthesis (3-D mammography) is better able to show infiltrating ductal carcinoma than 2-D mammography in women at increased risk of breast cancer, a new clinical study shows.

As part of the study, six breast imaging specialists reviewed both 2-D and 3-D mammography images of 56 cancers diagnosed in patients at intermediate or high risk of breast cancer.

"We found that 41 percent (23/56 cancers) were better seen on tomosynthesis and 4 percent (2/56) were only seen on tomosynthesis," said Sarah O'Connell, a lead author of the study. Thirty percent of cancers (17/56) were better seen on 2-D mammography but none were only seen on 2-D mammography. The remaining were rated by the breast imaging specialists as being equally visible on both 2-D and 3- imaging, she said.

"The majority of cancers seen better or only on tomosynthesis were predominantly infiltrating ductal carcinoma, which typically presents as a mass, focal asymmetry or architectural distortion," said O'Connell.

The majority of cancers seen better or only on 2-D mammography were ductal carcinoma in situ (DCIS) which presents as calcifications, she said. "This was not surprising because tomosynthesis gives us the ability to scroll through the breast tissue in 1 mm sections, which provides us with more detail, but also may separate a cluster of calcifications, making them more difficult to identify," said O'Connell. O'Connell noted that work is being done to optimize visualization of calcifications on tomosynthesis.

The benefits of tomosynthesis are especially relevant to women at increased risk of breast cancer who have increased anxiety about breast screening and have the potential for biologically aggressive cancers, said O'Connell.

The study is part of the electronic exhibit program at the ARRS Annual Meeting in Washington, D.C.


Related Content

News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its ...

Time January 28, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
Subscribe Now